On July 1, 2021 the St. Paul's Hospital Clinical Laboratory in Vancouver launched the Alzheimer's disease biomarker testing program for all Canadians.
Read the story here:
This first-in-Canada program was made possible via the IMPACT-AD study. The IMPACT-AD British Columbia and IMPACT-AD Canada studies were launched to help Canadians develop a comprehensive understanding of how Alzheimer’s disease biomarker testing impacts medical and personal decision making, and health care costs. The goal of IMPACT-AD is to inform positive change in the Canadian health care system to improve care and support for individuals living with Alzheimer’s disease, and their families.